On Tuesday, Axcelis Technologies Inc (NASDAQ:ACLS)’s shares inclined 1.34% to $3.03.
Axcelis Technologies Inc (ACLS) a leading supplier of enabling ion implantation solutions for the semiconductor industry, declared that it has received a multi system, follow on order for the Purion XE™ high energy implanter from a major chipmaker in the Asia Pacific Region. The systems will be used to support a capacity expansion for 3D NAND Flash devices. The systems are planned to ship in the third quarter.
The Purion Platform
The Purion platform redefines the ion implanter application space, delivering unmatched purity, precision and productivity to enhance customers’ device performance and yield. On this platform, we’ve built the industry’s first complete implant product solution designed specifically for advanced planar and 3D devices while providing the most flexible and productive manufacturing capability for your fab. The systems’ common cross-product platform architecture is designed to drive manufacturing flexibility and lower the total cost of fab operations. All Purion implanters incorporate Axcelis’ industry leading Purion Contamination Shield™ Defense System, for unsurpassed implant quality, so even the most sensitive devices can realize optimized device performance. The platform’s proprietary Purion Vector™ dose and angle control system, and constant focal length scanning deliver the most precise and repeatable dopant placement accessible recently. The platform’s superior beam current performance combined with the Purion™ 500wph end station provides the industry’s highest productivity. The Purion platform comprises the Purion M™ medium current implanter, the Purion H™ high current implanter, and the Purion XE™ high energy implanter.
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips worldwide. It provides offers a line of high energy, high current, and medium current implanters for all application requirements.
Blackstone Group LP (NYSE:BX)’s shares dropped -0.12% to $42.12.
Blackstone Group LP (BX) will acquire commercial real estate debt assets from Mubadala GE Capital Ltd. as Abu Dhabi investor Mubadala Development Co. weighs the future of its joint venture with General Electric Co.
Blackstone, the biggest real estate private equity firm, will pay cash for the debt, which accounts for 8 percent of Mubadala GE Capital’s total assets at the end of May, the joint venture said in an e-mailed statement Friday. It gave no valuation for the assets.
General Electric set up the $8 billion venture with Mubadala in 2008 to profit from commercial investments in the Middle East and Africa. Each company planned to contribute $4 billion in equity over three years to the fund, aiming to reach $40 billion in assets, they said at the time.
Mubadala GE Capital said the price of the assets sold to Blackstone is subject to customary adjustment and the deal could be terminated under certain circumstances.
Abu Dhabi-owned Mubadala is seeking buyers for GE’s 50 percent stake in Mubadala GE Capital, as the U.S. Company plans to exit from most General Electric Capital Corp. businesses, Reuters stated earlier this month, citing two people it didn’t identify. Mubadala is “in the process of evaluating a range of options for the future structure of the business,” a company spokesman said June 5.
The Blackstone Group L.P. is a publicly owned investment manager. The firm also provides financial advisory services to its clients. It provides its services to public and corporate pension funds, academic, cultural, and charitable organizations. The firm manages separate client focused portfolios. It launches and manages private equity funds, real estate funds, funds of hedge funds, and credit-focused funds for its clients. It invests in private equity, public equity, fixed income, and alternative investment markets. The firm was founded in 1985 and is based in New York, New York.
At the end of Tuesday’s trade, Pernix Therapeutics Holdings Inc (NASDAQ:PTX)‘s shares dipped -6.74% to $5.40.
Bellamy Young, actress and singer, best known for her role as First Lady ‘Mellie’ Grant on ABC’s drama “Scandal”, has partnered with Pernix Therapeutics (PTX), the makers of TREXIMET®, to share her experience with migraines in conjunction with National Migraine Awareness Month. As one of the more than 36 million Americans1 who suffer from migraines, Bellamy hopes to drive national awareness of the impact migraines can have, particularly in the summer when warmer weather and shifts in daily routines may trigger symptoms.
As Bellamy is well aware, the unpredictable, intense pain of migraines often impacts sufferers’ personal and professional lives in a meaningful way. In fact, a new survey conducted by Everyday Health, Inc., on behalf of Pernix Therapeutics revealed that 8 in 10 female migraine sufferers2said having migraines makes them feel less in control of their lives, while half agreed their personal relationships suffer because of their migraines.
The survey also found:
- Female migraine sufferers get frustrated (87%) when they feel like they have done everything right, yet still have migraines.
- While only 36% of physicians ask about how migraines have affected their careers, nearly all (96%) female migraine suffers find it difficult to work when they have migraines and almost half (48%) have missed at least one day of work in the past month due to migraines.
- Migraine suffering moms feel especially guilty (91%) when they miss out on quality time with their children because of their migraines.
Female migraine sufferers spend an average of 4 hours per week planning for a potential migraine and few women (29%) are very satisfied with their prescription medication. Fortunately, there are solutions that may assist manage the unpredictable nature of migraines to allow sufferers to take back control when a migraine starts.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The companys product comprise CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product.
Huntsman Corporation (NYSE:HUN), ended its Tuesday’s trading session with 1.12% gain, and closed at $23.50.
Huntsman Corporation (HUN) declared that it has accomplished the acquisition of Tecnoelastomeri, a manufacturer and marketer of methylene diphenyl diisocyanate (MDI) based hot-cast elastomer systems and processing machines, based in Modena, Italy. 2014 sales revenue for Tecnoelastomeri was about $12 million. The purchase price was not revealed.
Hot-cast polyurethanes are used in many downstream applications, counting bumper pads, coated conveyor belts, gears, rollers and wheels. These applications are used in the automotive, rail, oil and gas, mining and steel industries among others. Huntsman has supplied MDI for these applications for many years.
Huntsman Corporation, together with its auxiliaries, manufactures and sells differentiated organic and inorganic chemical products worldwide. The company operates in five segments: Polyurethanes, Performance Products, Advanced Materials, Textile Effects, and Pigments and Additives. The Polyurethanes segment offers polyurethane chemicals, counting methyl diphenyl diisocyanate, propylene oxide, polyols, propylene glycol, thermoplastic polyurethane, aniline, and methyl tertiary-butyl ether products, which are used to produce rigid and flexible foams, in addition to coatings, adhesives, sealants, and elastomers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
